AVENUE THERAPEUTICS, INC. (ATXI): Nasdaq/NYSE listing notice — Avenue Therapeutics receives Nasdaq delisting notice for equity deficiency; intends to request hearing

AVENUE THERAPEUTICS, INC.

Stockholders' equity of $1.652M as of Sep 30, 2024, below Nasdaq's $2.5M minimum requirement.
Delisting determined due to prior Panel Monitor; company ineligible for 180-day extension submission.
Trading continues; company must request hearing by Dec 3, 2024, to stay delisting.
Company believes equity compliance regained per Q3 10-Q Note 9; will demonstrate at hearing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2024 reported stockholders’ equity of $1,652,000. In a decision dated June 3, 2024, a Nasdaq Hearings Panel (the “Panel”) previously had confirmed that the Company regained compliance with the Stockholders’ Equity

View on SEC.gov

Browse all listing & compliance notices →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-124081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.